Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Favourable analyst view
About
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI
Target Price
The average target price of VCEL is 58 and suggests 59% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell